Similar articles

• [Physiological trials with MIF-I in Parkinson's disease (author's transl)].

  Gonce M, Barbeau A. Gonce M, et al. Rev Neurol (Paris). 1978 Feb;134(2):141-9. Rev Neurol (Paris). 1978. PMID: 29330 Clinical Trial. French.
• [The influence of MIF (melanocyte-stimulating hormone-release inhibiting factor) on psychomotor function and mood in parkinsonian patients. Preliminary report (author's transl)].

  Schneider E, Fischer PA, Jacobi P, Reh W. Schneider E, et al. Arzneimittelforschung. 1978;28(8):1296-7. Arzneimittelforschung. 1978. PMID: 37848 Clinical Trial. German.
• Rapid antidepressant activity of melanocyte-inhibiting factor: a clinical trial.

  Levy MI, DeNigris Y, Davis KL. Levy MI, et al. Biol Psychiatry. 1982 Feb;17(2):259-63. Biol Psychiatry. 1982. PMID: 6122475 Clinical Trial. No abstract available.
• Neurological effects of MIF-1, MSH, and opiate peptides in clinical studies.

  Kastin AJ, Ehrensing RH, Olson RD, Coy DH. Kastin AJ, et al. Int J Neurol. 1980;14(2-4):205-9. Int J Neurol. 1980. PMID: 6152908 Review. No abstract available.
• [Melanostatin (MIF-1): central action and clinical use].

  Puciłowski O, Płaźnik A, Kostowski W. Puciłowski O, et al. Pol Tyg Lek. 1983 Jun 13;38(24):739-41. Pol Tyg Lek. 1983. PMID: 6139794 Review. Polish. No abstract available.